secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2021-07-07T23:59:59+00:00
Accession:  0001193125-21-209988
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics appoints Christine Pellizzari to board, enters new exec employment agreements
--------------------------------------------------------------------------------

- Appointed Christine Pellizzari as Class II Director, serving on Audit Committee; term expires 2023.
- CEO Stephen Brady gets $475,283 base salary, 40% target bonus, 250k stock options, and severance of 12–18 months salary plus bonus.
- President Thomas Dubensky gets $476,283 base, 40% target bonus, 250k options; severance of 12–18 months salary plus bonus.
- CMO Samuel Whiting gets $400k base, 35% target bonus; severance of 9–12 months salary plus bonus.
- All directors and executive officers entered indemnification agreements with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/0001193125-21-209988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312521209988/d69289d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-209988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer